

POSTER PRESENTATION

Open Access

# Selinexor, a selective inhibitor of nuclear export (SINE), shows enhanced activity in combination with PD-1/PD-L1 blockade in syngeneic murine models of colon cancer and melanoma

Matthew R Farren<sup>1\*</sup>, Reena Shakya<sup>2</sup>, Rebecca Hennessey<sup>3</sup>, Thomas Mace<sup>4</sup>, Jennifer Yang<sup>1</sup>, Omar Elnaggar<sup>1</sup>, Gregory Young<sup>5</sup>, Yosef Landesman<sup>6</sup>, Robert Carlson<sup>6</sup>, Sivan Elloul<sup>6</sup>, Marsha Crochiere<sup>6</sup>, Christin Burd<sup>3</sup>, Gregory Lesinski<sup>1</sup>

From 30th Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2015) National Harbor, MD, USA. 4-8 November 2015

Exportin-1 (XPO1) is a nuclear export protein with >220 cargo proteins, including tumor suppressors and cell cycle modulators. Selinexor is a SINE (Selective Inhibitor of Nuclear Export) compound that has been administered to >900 cancer patients in Phase I and II trials to date, with evidence of efficacy and tolerability. Selinexor blocks nuclear export of NFAT1c, STAT1 and STAT3, which are implicated in regulating the inhibitory T cell receptor PD-1 and its ligand, PD-L1. We hypothesized that selinexor would upregulate T cell checkpoint molecule expression, and that combination treatment with anti-PD-1 or anti-PD-L1 would thereby enhance the ability of selinexor to elicit antitumor activity.

Selinexor increased PD-1 gene expression by ~2-fold in normal lymphocytes and induced PD-L1 gene expression in tumor cell lines. Mice bearing syngeneic colon tumors (colon26) treated with selinexor and anti-PD-1 for 2 weeks demonstrated a significant reduction in tumor growth rate ( $P < 0.05$ ), while monotherapy with either agent had no significant effect on tumor growth. Similar results were obtained in mice bearing syngeneic B16F10 melanoma tumors, whereby combined treatment with selinexor + anti-PD-1 was superior to either single agent alone ( $p < 0.034$ ). Combined therapy of mice bearing B16F10 tumors with selinexor and anti-PD-L1 was similarly effective, with significantly smaller tumors

at the study endpoint ( $p < 0.001$ ). No weight loss or signs of toxicity were evident in any *in vivo* study.

Immunophenotypic analysis by flow cytometry revealed that selinexor alone or in combination with anti-PD-1/anti-PD-L1 significantly increased the percentage of splenic NK cells ( $p \leq 0.050$ ), while selinexor ± anti-PD-L1 significantly increased the percentage of splenic Th1 T cells ( $p \leq 0.011$ ), all compared to vehicle treated mice. Interestingly, combining selinexor with anti-PD-L1 significantly decreased the percentage of splenocytes that expressed PD-L1 ( $p < 0.001$ ). These data indicate that the efficacy of selinexor may be enhanced by disrupting the pre-existing PD-1/PD-L1 signaling in effector cells (T and NK cells).

Altogether, these data suggest that the efficacy of selinexor in combination with anti-PD-1 or anti PD L1 in mouse syngeneic tumor models may be due to both disrupting immunosuppressive PD-1/PD-L1 signaling and increasing the frequency of potentially tumor reactive NK cells and Th1 T cells. This provides a rational basis for this treatment combination as a novel therapeutic approach for advanced cancer.

#### Authors' details

<sup>1</sup>Department of Internal Medicine, James Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA. <sup>2</sup>The Ohio State University, Columbus, OH, USA. <sup>3</sup>Department of Molecular Genetics, James Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA. <sup>4</sup>Department of Internal Medicine, James Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA. <sup>5</sup>Center for Biostatistics, The Ohio State University, Columbus, OH, USA. <sup>6</sup>Karyopharm Therapeutics, Newton, MA, USA.

<sup>1</sup>Department of Internal Medicine, James Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA  
Full list of author information is available at the end of the article

Published: 4 November 2015

doi:10.1186/2051-1426-3-S2-P355

**Cite this article as:** Farren *et al.*: Selinexor, a selective inhibitor of nuclear export (SINE), shows enhanced activity in combination with PD-1/PD-L1 blockade in syngeneic murine models of colon cancer and melanoma. *Journal for ImmunoTherapy of Cancer* 2015 **3**(Suppl 2):P355.

**Submit your next manuscript to BioMed Central  
and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at  
[www.biomedcentral.com/submit](http://www.biomedcentral.com/submit)

